InvestorsHub Logo
Followers 21
Posts 1676
Boards Moderated 0
Alias Born 07/09/2005

Re: None

Tuesday, 12/29/2020 5:43:52 PM

Tuesday, December 29, 2020 5:43:52 PM

Post# of 2794
Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial
- 100% rate of BMT and engraftment in patients receiving therapeutic dose of Iomab-B and lower rates of sepsis and sepsis related Grade ≥3 adverse events compared to patients receiving salvage therapies at 75% enrollment recently highlighted in oral presentations at ASH 2020 Annual Meeting

- Independent Data Monitoring Committee recommends SIERRA continue as planned to full enrollment of 150 patients; trial is currently over 75% enrolled

- SIERRA trial remains the only randomized Phase 3 trial to offer potentially curative bone marrow transplant as an option for patients with active relapsed or refractory AML

More here-Tables to review
https://www.prnewswire.com/news-releases/actinium-announces-successful-pre-planned-ad-hoc-interim-analysis-of-phase-3-sierra-trial-301198869.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ATNM News